{
  "id": "63f03006f36125a426000018",
  "type": "summary",
  "question": "What were the results of the DESTINY-Breast04 Trial?",
  "ideal_answer": "DESTINY-Breast04 Trial found that in HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
    "http://www.ncbi.nlm.nih.gov/pubmed/35666611"
  ],
  "snippets": [
    {
      "text": "METHODS: We conducted a phase 3 trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. (Low expression of HER2 was defined as a score of 1+ on immunohistochemical [IHC] analysis or as an IHC score of 2+ and negative results on in situ hybridization.) Patients were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan or the physician's choice of chemotherapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast04 ClinicalTrials.gov number, NCT03734029.).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Findings from the phase III DESTINY-Breast04 trial indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35666611",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}